Teriparatide vs NA-Selank Amidate
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Teriparatide
Teriparatide (Forteo) is recombinant human parathyroid hormone (1-34), FDA-approved for osteoporosis treatment. It's unique among osteoporosis drugs in that it stimulates new bone formation.
Full details →NA-Selank Amidate
NA-Selank Amidate (N-Acetyl Selank Amidate) is an enhanced version of Selank with improved stability and blood-brain barrier penetration. The modifications increase bioavailability and duration of cognitive and anxiolytic effects.
Full details →Side-by-Side Comparison
| Aspect | Teriparatide | NA-Selank Amidate |
|---|---|---|
| Mechanism | Intermittent PTH exposure paradoxically stimulates osteoblasts more than osteoclasts, resulting in net bone formation. Continuous exposure would cause bone loss, but pulsatile dosing builds bone. | Same core mechanism as Selank - modulates BDNF, serotonin, and norepinephrine systems. The N-acetyl group improves membrane permeability while the amidate modification increases enzymatic stability. |
| Typical Dosage | 20mcg subcutaneously once daily. Maximum treatment duration of 2 years due to theoretical osteosarcoma risk from rat studies. | Intranasal: 100-400mcg 1-3 times daily. Lower doses needed compared to standard Selank due to enhanced bioavailability. |
| Administration | Subcutaneous injection in thigh or abdomen once daily. Delivered via multi-dose pen. Should sit or lie down after injection due to orthostatic hypotension risk. | Primarily intranasal administration. Can be used sublingually. More stable in solution than standard Selank. |
| Side Effects | Orthostatic hypotension, leg cramps, nausea, dizziness, headache, and injection site reactions. Transient hypercalcemia possible. | Generally well-tolerated. Possible mild fatigue or nasal irritation. Less frequent dosing needed than standard Selank. |
| Best For |